|Over a week ago|
InMed Pharmaceuticals announces milestones for 2023 » 07:3601/1001/10/23
InMed Pharmaceuticals outlines key accomplishments from 2022 and provides business update and catalysts for 2023. Business update and upcoming milestones: INM-755 - Phase 2 clinical trial in the treatment of Epidermolysis Bullosa. To date, the Phase 2 clinical trial has enrolled 16 patients of its targeted 20 patients. Several additional prospective patients have been identified for screening at the clinical sites; therefore, the Company decided to extend the enrollment period to the end of March 2023. INM-088 - Advancing towards human trials: The Company continues to conduct the required preclinical work, including toxicology studies, and has planned several GLP studies in 2023 in advance of human clinical trials. On track to begin this clinical trial in 2024. INM-900 - Developing a new approach in neurodegenerative disease: InMed's ipeline was expanded this year with the addition of our neurodegenerative disease program. With recent promising preclinical data, InMed plans to expedite its INM-900 program for the potential treatment of neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease. Novel cannabinoid analogs - protecting the R&D investment: InMed continues to develop a valuable library of novel, proprietary cannabinoid analogs. These analogs are being selectively screened and developed for targeting specific disease outcomes, safety profiles, and/or pharmacological properties such as improved delivery. In addition, these novel cannabinoid analogs are patentable, increasing their commercial attractiveness for internal development or as licensing candidates to other drug development companies.
InMed Pharmaceuticals price target lowered to $45 from $53 at Cowen » 07:3001/0901/09/23
Cowen analyst Ritu Baral…
Cowen analyst Ritu Baral lowered the firm's price target on InMed Pharmaceuticals to $45 from $53 and keeps an Outperform rating on the shares. The analyst updated his model to reflect guidance and adjusted his target and forward estimates for growth and WW revenues while also noting the ASPEN study remains on track while brenso Ph2 PK/PD was clean.
|Over a month ago|
Sell these stocks now, proven algorithm says » 14:3612/1612/16/22
INM, MRTX, SE, TOST, SHOP, EQX, CFLT, XMTR, RADI, PL, PSFE, FREY, VERV, CCL, EVA, RXRX, MAXR
Here are this week's…
InMed Pharmaceuticals engages Marcum LLP as auditor after KPMG resigns » 18:5112/1212/12/22
The Company "announces that its auditor, KPMG has resigned effective as of December 8, 2022, and that the Audit Committee of the Board of Directors of the Company approved the engagement of Marcum LLP as its auditor, subject to Marcum's completion of their client acceptance procedures. Marcum will stand for appointment at the Company's Annual General Meeting, currently scheduled for Thursday, December 15, 2022. KPMG has confirmed that there are no reportable events (as such term is defined in National Instrument 51-102 - Continuous Disclosure Obligations."
InMed Pharmaceuticals names Jonathan Tegge as interim CFO » 18:4912/1212/12/22
InMed Pharmaceuticals "announces the Company has entered into a service contract with Brio Financial Group to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022."
InMed Pharmaceuticals announces $6M private placement » 08:0711/1811/18/22
InMed Pharmaceuticals announced that it has entered into a securities purchase agreement with two healthcare-focused institutional investors for the issuance and sale of 1,818,185 of its common shares at a purchase price of $3.30 per share in a private placement priced at-the-market under Nasdaq rules. In addition, the Company has agreed to issue to the investors in the offering unregistered preferred investment options to purchase up to an aggregate of 3,272,733 common shares. The aggregate gross proceeds to the Company from the private placement is expected to be approximately $6 million. The offering is expected to close on or about November 21, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to continue pipeline development of its pharmaceutical drug candidates, advance manufacturing know-how of cannabinoids and cannabinoid analogs, support intellectual property development and other commercial activities, and for general working capital purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The unregistered investment options to be issued in the offering will be exercisable immediately upon issuance at an exercise price of $3.044 per share and will expire seven years from the date of issuance. In addition, the investors in the private placement agreed to cancel preferred investment options to purchase up to an aggregate of 1,382,490 common shares of the Company which were previously issued to the investors.
InMed Pharmaceuticals annouces Li promoted to VP of accounting, controller » 07:3111/1711/17/22
InMed Pharmaceuticals announces that Sarah Li has been promoted to Vice President, VP, of Accounting and Controller at InMed. Brenda Edwards will be transitioning out of her position as interim Chief Financial Officer at the Company effective November 20, 2022. Edwards joined the Company in an interim contract role to assist the Company with financial reporting matters following the retirement of the Company's former Chief Financial Officer in March 2022. The Company is currently in discussions to finalize the engagement of interim financial leadership consulting services.
InMed Pharmaceuticals announces launch of neurodegenerative disease program » 07:1511/1611/16/22
InMed Pharmaceuticals announces the launch of its neurodegenerative disease program, which will be investigating the effects of cannabinoid analogs in diseases such as Alzheimer's, Huntington's and Parkinson's. In research conducted to date, InMed has identified two cannabinoid analogs demonstrating promising effects related to the treatment of neurodegenerative diseases, warranting further investigation in in vivo studies. InMed will be conducting studies using in vivo models in neurodegenerative disease to select the most appropriate candidate for clinical studies. Early preclinical efficacy readout is expected in 2Q 2023. In addition, Dr. Ujendra Kumar of the faculty of Pharmaceuticals Sciences at UBC has been awarded an Alliance grant from NSERC, with InMed as the named industry partner. The funding will support the research and development studies of InMed's cannabinoid pharmaceutical candidates, investigating their potential therapeutic effects in neurodegenerative diseases. The collaboration project is entitled "Pharmacological characterization of phytocannabinoids and the endocannabinoid system."
InMed Pharmaceuticals reports Q1 EPS ($4.06) vs. ($6.17) a year ago » 18:5711/1111/11/22
The company realized…
The company realized sales of $0.3M in the BayMedica segment for the for the three months ended September 30, 2022, the result of the manufacturing and sale of bulk rare cannabinoid products following the acquisition of BayMedica in October 2021. As the period ended September 30, 2021 predated the acquisition of BayMedica, there are no comparable revenues in 2021.
|Over a quarter ago|
InMed Pharmaceuticals files to sell 2.07M shares of common stock for holders 06:1110/1210/12/22